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New diagnostic criteria for Acute Kidney Injury
The occurrence of renal dysfunction in patients with cirrhosis is 
a harbinger of very poor clinical outcome. Nearly 19 years after 
the previous criteria for the diagnosis of hepatorenal syndrome 
was made, the International Ascites Club, which is comprised of 
investigators and clinicians from around the world, have produced 
a Position statement to re-define the syndrome. This marks a 
paradigm shift from the previous criteria, where a change in levels 
of creatinine is introduced as the key variable allowing patients 
to be started on therapy much earlier. The new definitions allow 
for the future incorporation of novel biomarkers to differentiate 
between the types of renal dysfunction and should allow earlier and 
potentially more targeted therapies.Angeli et al., 2015LIVER FIBROSIS
norUDCA for liver 
inflammation
In Abcb4/Mdr2-/- (canalicular 
phospholipid export pump/
multidrug resistance protein 
2) mice, representing a well 
characterized systems model 
for sclerosing cholangitis and 
biliary type of liver fibrosis, 
there is evidence of a potential 
direct anti-inflammatory and 
anti-fibrotic effect of 24-nor-
ursodeoxycholic acid (norUDCA, 
a side chain-shortened bile 
acid). However, it remains 
unclear whether this promising 
compound is able to exert 
beneficial mechanisms in 
non-cholestatic types of liver 
fibrosis. Sombetzki et al. using 
a murine model of hepatic 
schistosomiasis found marked 
anti-inflammatory and anti-
fibrotic effects of norUDCA 
compared to UDCA in 
Schistosoma mansoni-induced 
liver injury. They showed that 
norUDCA directly represses 
antigen presentation of antigen 
presenting cells and subsequent 
T-cell activation in vitro. They 
conclude that norUDCA 
represents a promising drug for 
the treatment of this important 
cause of liver fibrosis.
LIVER CANCER
ER stress promotes 
cancer, novel predictors 
of HCC prognosis
The accumulation of misfolded 
proteins in the lumen of 
hepatocyte endoplasmic 
reticulum (ER) causes ER 
stress. This stress triggers a 
cell response called unfolded 
protein response (UPR) 
which aims to restore protein 
folding, ER homeostasis and, 
ultimately, favor cell survival. 
ER-to-nucleus signals induce 
the transcription of a battery of 
genes including those encoding 
chaperones such as gp96 also 
called grp94, endoplasmin, 
ERp99 or HSP90B1. The role 
of gp96 in the context of liver 
cancer is unknown. Richidi et al. 
addressed this question using 
different approaches including 
genetic and pharmacological 
gp96 inhibition. They found 
significant pro-survival/pro-
oncogenic effects mediated 
by gp96, suggesting that this 
chaperone maybe a target for 
future therapies. 
Prothrombin induced by vitamin 
K absence-II (PIVKA-II, des-
gamma carboxy prothrombin, 
an abnormal form of the Sombetzki et al., 2015
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This issue of the Journal 
contains three intriguing articles 
on the mechanisms linking 
obesity and NAFLD. The vagus 
nerve is known to relay signals 
between liver and brain that 
regulate peripheral adiposity. 
Gao et al. demonstrated that 
neuronal signals via the hepatic 
vagus nerve contribute to the 
development of steatohepatitis 
and protection against obesity 
in mice that have an impaired 
phosphatidylcholine synthesis. 
These results suggest that 
the development of fatty liver 
is partially regulated by the 
nervous system. Future studies 
should confirm if this novel 
mechanism is also present in 
humans with NAFLD. Obesity 
and the resulting NAFLD are 
associated with increased 
cardiovascular risk, and 
recent evidence suggests a 
possible role for epicardial 
fat. Petta et al. tested the 
correlation between epicardial 
fat and severity of NAFLD. 
They convincingly demonstrate 
that in patients with NAFLD, a 
higher epicardial fat thickness 
is associated with the severity 
of liver fibrosis, suggesting 
a possible pathogenic role of 
ectopic fat depots in whole 
body organ damage. This study 
suggests that regardless of the 
anatomical location, excess 
fat accumulation can influence 
NAFLD development. Finally, 
an elegant study by Anjani et 
al. performed an extensive 
lipidomic analysis of portal and 
systemic circulation in patients 
with NAFLD that underwent 
bariatric surgery to identify 
forms of NAFLD. 
Whether alcohol consumption 
has beneficial or deleterious 
effects on the development 
of NAFLD is a matter of 
controversy. Moriya et al. 
performed a large longitudinal 
study in 5297 Japanese 
individuals to address this 
question. The authors provide 
evidence that light to moderate 
alcohol consumption was 
likely to protect most individuals 
against fatty liver over time. 
This study confirms previous 
reports indicating that moderate 
alcohol consumption could have 
beneficial effects in NAFLD. 
Further longitudinal studies in 
different populations should 
confirm these results. 
VIRAL HEPATITIS C
Virus recognition 
by cytosolic innate 
immune receptors, virus 
escape to the innate 
immune response, 
P-bodies inhibition, lipid 
metabolism according 
to genotype 
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Type I and III interferons 
are critically involved in the 
clearance of acute HCV 
infection and triggered by an 
important family of cytoplasmic 
innate pattern recognition 
receptors – the RIG-I-like 
helicases (RLHs). Cao et al. 
now demonstrated for the first 
time that interferon activation 
is mainly dependent upon the 
RLH melanoma differentiation-
associated gene 5 (MDA-5) 
and not, as previously thought, 
by RIG-I. These findings provide 
new clues to the phenomenon 
how host cells may sense HCV 
in order to initiate the interferon 
signaling during HCV infection.
The HCV NS3-4A protease 
interferes with interferon 
signaling by its capacity 
to cleave and inactivate 
mitochondrial antiviral-signaling 
protein (MAVS), the main 
adaptor molecule in the RIG-I-
like helicase pathway hereby 
promoting viral persistence. In 
an elegant proof-of-concept 
study, Welsch et al. showed 
that resistance-associated 
variants (RAVs) which are 
selected specifically for 
patients under treatment with 
macrocylic protease inhibitors 
have an increased capacity to 
cleave MAVS. These new data 
underline that certain RAVs may 
be related to other pathogenic 
events besides their association 
with treatment failure. 
Péres-Vilaró et al. describe a 
new host viral interaction that 
indicates a specific inhibition 
of P-body formation in human 
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Healthy liverclotting factor prothrombin) is 
a diagnostic and surveillance 
marker for HCC mainly used 
in Asia, and has also been 
shown to be a predictor of 
microvascular invasion, a 
major prognostic factor in HCC. 
However, the prognostic value 
of PIVKA-II in Caucasians 
is unknown. Poté et al. 
investigated serum levels and 
tissue expression of PIVKA-II 
in a French cohort including 43 
control patients with cirrhosis 
and 85 patients with HCC. They 
found that PIVKA-II was more 
efficient than α-fetoprotein 
for the diagnosis of early 
HCC, and could be used as 
a predictive biomarker of 
microvascular invasion.
TACE (transarterial 
chemoembolization) is the most 
commonly used treatment for 
HCC worldwide. In Europe and 
the USA, TACE is the standard 
of care for intermediate (BCLC 
B) stage HCC. In the context 
of HCC, overall survival is 
a composite that integrates 
cancer-related and liver 
disease-related components of 
prognosis. Having predictors 
of overall survival for patients 
with HCC treated with repeated 
TACE is an unmet medical need. 
Adhoute et al. used a regression 
model to analyze data from 
139 consecutive patients 
with HCC treated by TACE. 
Four prognostic factors were 
predictors of overall survival: 
higher BCLC and α-fetoprotein 
(>200 ng/ml) at enrollment, 
increase in Child-Pugh score by 
≥2 above value at enrollment, 
and absence of radiological 
response. These four predictors 
were included in a score (ABCR) 
ranging from -3 to +6 that was 
correlated with survival and 
allowed to identify three groups 
with different survival rates. 
This score was validated in two 
different cohorts of 178 patients. 
Of note Adhoute et al. showed 
that an ABCR score >4 prior 
to the second TACE identifies 
patients with poor prognosis 
in which further TACE 
sessions could be futile.FATTY LIVER DISEASES
Role of the vagus nerve, 
epicardial fat, portal 
phospholipidis and 
alcohol consumption in 
NAFLD
potential disease drivers. They 
found 2 phospholipids in the 
portal vein that were increased 
compared to the systemic 
circulation in patients with 
NASH. These results suggest 
that lipid mediators could 
mediate the effect of visceral fat 
in the development of severe Péres-Vilaró et al., 2015
P-body recovery
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hepatocytes by HCV can 
occur independently from viral 
genotype, inflammation grade 
or duration of infection. Thus 
this study links for the first 
time a pathogenic condition to 
P-body alterations. Reflecting 
the important role of P-bodies in 
cellular gene expression, their 
alteration can be considered 
as an important hint for a better 
understanding of the complex 
HCV-associated pathologies. 
Bridge et al. conducted 
interesting studies on HCV 
genotype-specific differences 
in lipoprotein interactions 
and found that HCV type 3 
influences lipid metabolism 
differently from HCV type 1. 
These findings may also indicate 
that statins are more beneficial 
as adjunct therapy in HCV type 
1 as compared to type 3. 
VIRAL HEPATITIS B
HBV genotype G
There is increasing interest 
to understand better the 
HBV genotype-specific 
pathogenesis. Peiffer et al. 
characterized elegantly the 
molecular properties of the 
non HBeAg-secreting HBV 
genotype G in comparison 
to HBV type A. Observed 
differences in the viral life cycle 
and changes in the capacity 
of HBV/G expressing cells 
to inactivate oxidative stress 
mechanisms are of potential 
relevance for the concept of 
a specific virus-associated 
pathogenesis.
CIRRHOSIS
The new CLIF C-AD 
score, effect and 
mechanism of action of 
albumin and bleeding in 
alcoholic hepatitis
Patients with cirrhosis admitted 
to hospital have a high mortality. 
It is clear that the mortality 
rates in those that fulfill criteria 
for diagnosis of acute-chronic 
liver failure (ACLF) is high but 
in a small group of patients 
without ACLF, there is a high 
probability of progressing 
to ACLF. The EASL-CLIF 
Consortium have developed 
and validated a new score, 
the CLIF C-AD score to define 
the prognosis of hospitalized 
cirrhotic patients without 
ACLF. Garcia-Martinez et al. 
performed a mechanistic study 
in analbuminemic rodents 
and endothelial cells, and 
showed that albumin has 
immunomodulatory and 
anti-inflammatory actions 
and, acts intracellularly in 
endothelial cells to reduce 
oxidative stress. However, 
in a randomized clinical trial 
of albumin administration by 
Thevenot et al. showed that 
albumin administration 
did not improve survival in 
cirrhotic patients hospitalized 
with non-SBP infections. 
An accompanying editorial 
suggested that the trial may 
be underpowered and a larger 
European study, the INFECIR-2 
study has been launched. An 
important study by the Thabut 
group showed convincingly that 
the survival of patients with 
acute alcoholic hepatitis is 
not altered by the presence 
of gastrointestinal bleeding 
but make the important and 
perhaps surprising observation 
of less infection rates in those 
with bleeding, perhaps because 
of early administration of 
antibiotics.
GUIDE FOR AUTHORS
Modification of the 
STARD evaluation 
criteria for hepatic 
fibrosis
The STARD (for STAndards 
for the Reporting of Diagnostic 
accuracy studies) checklist is 
the standard that is generally 
required for the evaluation 
of diagnostic studies. In this 
study, by Boursier et al. eight 
French experts evaluated the 
adequacy of the STARD and 
found that this was not accurate 
to evaluate diagnostic studies 
in fibrosis. They developed 
and independently evaluated 
a novel, bespoke and fit-for-
purpose reporting format, the 
Liver-FibroSTARD checklist 
for the evaluation of fibrosis 
biomarker studies. Discussions 
to implement this are underway 
as a standard for reporting.
CHOLESTASIS
Autotaxin: A novel 
biomarker of 
intrahepatic cholestasis 
of pregnancy
The autotaxin protein 
(which is encoded by 
ENPP2, for ectonucleotide 
pyrophosphatase/
phosphodiesterase 2) functions 
as both a phosphodiesterase, 
which cleaves phosphodiester 
bonds at the 5’ end of 
oligonucleotides, and a 
phospholipase, which catalyzes 
production of lysophosphatidic 
acid (LPA) in extracellular fluids. 
LPA has been recently described 
as a novel, putative molecular 
protein underlying pruritus in 
cholestasis. Kremer et al. extend 
those observations to pregnant 
patients and show for the first 
time that autotaxin is a highly 
sensitive, specific and robust 
diagnostic marker of intrahepatic 
cholestasis of pregnancy, 
distinguishing it from other 
pruritic disorders of pregnancy 
and pregnancy-related liver 
diseases.
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